Similarly, next generation LOXL2 inhibitors are effective in pre-clinical models of gastric (83) and breast cancer (40, 84, 85) as well as lung and liver fibrosis models (86), with targeted therapeutics against LOXL2 currently undergoing Phase I/II testing (54). Here, LOXL2 is linked to breast cancer.